Vaderis Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vaderis Therapeutics is a private, clinical-stage biotech pioneering a first-in-class oral therapy for Hereditary Hemorrhagic Telangiectasia (HHT), a severe rare vascular disorder. The company's lead candidate, Engasertib, is a selective AKT1/2 inhibitor designed to correct the underlying vascular instability caused by HHT mutations. Backed by experienced leadership and venture capital investors like Medicxi and DROIA Ventures, Vaderis aims to address a significant unmet medical need in an underserved patient population. The company is currently in the clinical development phase, advancing its science from deep biological insight toward potential regulatory approval.

Rare Vascular DiseasesHereditary Hemorrhagic Telangiectasia (HHT)

Technology Platform

Targeted inhibition of AKT1/AKT2 to correct dysregulated BMP9/BMP10 signaling and restore vascular stability in rare vascular diseases like HHT.

Opportunities

First-to-market potential in HHT, a severe rare disease with no approved therapies and a clear unmet need.

The targeted AKT platform could be expanded to other rare vascular disorders with similar pathway dysregulation, creating a pipeline opportunity.

Risk Factors

High clinical development risk as the novel AKT inhibition mechanism is unproven in HHT patients.

Significant financing risk as a pre-revenue, private company dependent on venture capital to fund expensive clinical trials.

Competitive Landscape

The competitive landscape for HHT is currently sparse, with no approved pharmacotherapies, positioning Vaderis as a pioneer. However, other biotechs or academic groups may be exploring alternative approaches (e.g., gene therapy, ligand supplementation), and the significant unmet need could attract new entrants following positive proof-of-concept data.

More companies in Small Molecule Drugs →More companies in Switzerland →